You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
Title |
Progress in defining clinically meaningful changes for clinical trials in nonrenal manifestations of SLE disease activity
|
---|---|
Published in |
Arthritis Research & Therapy, January 2016
|
DOI | 10.1186/s13075-015-0906-9 |
Pubmed ID | |
Authors |
Chan-Bum Choi, Matthew H. Liang, Sang-Cheol Bae |
Abstract |
Since the 2002 Dusseldorf meeting, one new agent, Benlysta, has been approved by the US Food and Drug Administration for systemic lupus erythematosus. Experiences from the field in conducting trials of all the agents tested during this period have provided valuable practical insights. There has been incremental progress in defining the minimal clinically important difference (MCID) of key disease manifestations and the view is largely that of the health care providers and not that of the person suffering the disease. This basic methodological work on the MCID should improve the efficiency and the clinical relevance of future trials and their design. |
Mendeley readers
The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 42 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 8 | 19% |
Student > Master | 6 | 14% |
Student > Doctoral Student | 5 | 12% |
Student > Bachelor | 3 | 7% |
Librarian | 2 | 5% |
Other | 9 | 21% |
Unknown | 9 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 24 | 57% |
Nursing and Health Professions | 2 | 5% |
Immunology and Microbiology | 2 | 5% |
Computer Science | 1 | 2% |
Psychology | 1 | 2% |
Other | 1 | 2% |
Unknown | 11 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 January 2016.
All research outputs
#4,835,465
of 25,371,288 outputs
Outputs from Arthritis Research & Therapy
#1,027
of 3,380 outputs
Outputs of similar age
#75,073
of 400,104 outputs
Outputs of similar age from Arthritis Research & Therapy
#64
of 94 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,380 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.2. This one has gotten more attention than average, scoring higher than 64% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 400,104 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 94 others from the same source and published within six weeks on either side of this one. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.